Results 171 to 180 of about 4,101 (234)

PS1148 PRELIMINARY RESULTS OF A PHASE 1B/2 DOSE‐ESCALATION AND COHORT‐EXPANSION STUDY OF THE NONCOVALENT, REVERSIBLE BRUTON'S TYROSINE KINASE INHIBITOR (BTKI), VECABRUTINIB, IN B‐CELL MALIGNANCIES

open access: gold, 2019
John N. Allan   +14 more
openalex   +1 more source

Real-world clinical outcomes in patients with CLL previously treated with covalent BTKi and BCL2i regimens

open access: diamond
Jennifer Prescott   +10 more
openalex   +1 more source

Acalabrutinib treatment in relapsed/refractory primary cutaneous diffuse large B cell lymphoma, leg type. Case report. [PDF]

open access: yesFront Oncol
Martinez-Gamboa DA   +6 more
europepmc   +1 more source

Clinical practice guidelines for the diagnosis and management of chronic lymphocytic leukemia in Saudi Arabia: consensus statement by an expert panel. [PDF]

open access: yesFront Med (Lausanne)
Alotaibi G   +9 more
europepmc   +1 more source

Inhibition of bruton's tyrosine kinase directly alleviates pathogenic CD4+ T cell response via PPAR-γ signaling in autoimmune uveitis. [PDF]

open access: yesJ Neuroinflammation
Xiao Z   +13 more
europepmc   +1 more source

Two-year update of ZUMA-2 Cohort 3: Brexucabtagene autoleucel (Brexu-cel) in patients (pts) with relapsed/refractory mantle cell lymphoma (R/R MCL) who had not received prior Bruton tyrosine kinase inhibitor (BTKi) therapy [PDF]

open access: bronze
Tom van Meerten   +21 more
openalex   +1 more source

Survival Outcomes of Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) Treated in the Chemoimmunotherapy Vs BTK Inhibitor (BTKi) Eras: A European Research Initiative on CLL (ERIC) Study

open access: green
T C   +72 more
openalex   +2 more sources

Home - About - Disclaimer - Privacy